David B Glass

US Patent:

6735432, May 11, 2004

Filed:

Nov 4, 1998

Appl. No.:

09/185859

Inventors:

Keith Jarett - Oakland CA
Roland E. Williams - Walnut Creek CA
Michael A. Raffel - Redmond WA
Roderick Nelson - Redmond WA
Ileana A. Leuca - Bellevue WA
Tony S. Lee - Alameda CA
Christopher G. Lawrence - Kirkland WA
Masud Kibria - Kirkland WA
David R. Glass - Redmond WA
Michael D. Bamburak - Columbia MD

Assignee:

ATT Wireless Services, Inc. - Redmond WA

International Classification:

H04M 342

US Classification:

455417, 455421, 455434, 342457

Abstract:

A mobile station communicates with both a cellular network, by which it is assigned a mobile identification number, and to a cordless cellular base station utilizing the same cellular frequency range and communications protocol. The cordless cellular base station is preferably connected to a public switched telephone network and is assigned a landline number. The cordless cellular base station acts as a conduit between the mobile station and the public switched telephone network. When the mobile station comes within range of a cordless cellular base station, it deregisters automatically from the cellular network and register with the cordless cellular base station. Once the mobile station is communicating with the cordless cellular base station, the cordless cellular base station communicates with the cellular network to instruct the cellular network to route all calls for mobile identification number to the cordless cellular base stations landline number. In addition, all calls placed on the mobile station are sent through the cordless cellular base station to the public switched telephone network. When the mobile station severs contact with the cordless cellular base station, the mobile station registers with the regional cellular base station of the regional cellular network.

US Patent:

8343918, Jan 1, 2013

Filed:

Jun 6, 2007

Appl. No.:

12/304068

Inventors:

David Jonathan Glass - Cambridge MA, US
Mara Fornaro - Basel, CH

Assignee:

Novartis AG - Basel

International Classification:

A61K 38/30
C07K 14/65
C07H 21/04

US Classification:

514 86, 530324, 530345, 536 235

Abstract:

The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented.

US Patent:

20060216279, Sep 28, 2006

Filed:

Mar 22, 2006

Appl. No.:

11/388304

Inventors:

David Glass - Cambridge MA, US
Brian Clarke - Cambridge MA, US

International Classification:

A61K 38/54
C07H 21/04
C12N 9/99
C12P 21/06
C12N 1/21
C12N 5/06

US Classification:

424094200, 435069100, 435184000, 435252310, 435252330, 435358000, 514012000, 536023200

Abstract:

Myostatin inhibiting GDF8 and GDF11 fusion polypeptides and their encoding nucleic acids are disclosed. Pharmaceutical compositions comprising these fusion polypeptides or their corresponding nucleic acids and methods of use are also disclosed.

US Patent:

20110195077, Aug 11, 2011

Filed:

Jan 27, 2011

Appl. No.:

13/015159

Inventors:

David GLASS - Cambridge MA, US

Assignee:

NOVARTIS AG - Basel

International Classification:

A61K 39/395
C07K 19/00
A61K 38/47
C07H 21/04
A61P 17/00
A61P 21/00
A61P 9/10
A61P 19/10
A61P 37/00
A61P 25/28
A61P 27/02
A61P 27/12
A61P 35/00
A61P 27/16
A61P 13/12
A61P 3/00
A61P 3/10
A61P 3/04
C12N 9/96
C12N 5/00
C12N 15/63

US Classification:

4241781, 5303917, 5303919, 424 943, 536 234, 536 232, 435188, 435325, 4353201

Abstract:

The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23), or a functionally active variant or derivative thereof; and a modified Fc fragment, or a functionally active variant or derivative thereof. In various embodiments of the fusion polypeptides, FGF23 has mutations which decrease aggregation and protease-mediated cleavage.

US Patent:

59111208, Jun 8, 1999

Filed:

Sep 8, 1995

Appl. No.:

8/526066

Inventors:

Keith Jarett - Oakland CA
Roland E. Williams - Walnut Creek CA
Michael A. Raffel - Redmond WA
Roderick Nelson - Redmond WA
Ileana A. Leuca - Bellevue WA
Tony S. Lee - Alameda CA
Christopher G. Lawrence - Kirkland WA
Masud Kibria - Kirkland WA
David R. Glass - Redmond WA
Michael D. Bamburak - Columbia MD

Assignee:

AT&T Wireless Services - Kirkland WA
Atmel Corp - San Jose CA

International Classification:

H01S 400

US Classification:

455417

Abstract:

A mobile station communicates with both a cellular network, by which it is assigned a mobile identification number, and to a cordless cellular base station utilizing the same cellular frequency range and communications protocol. The cordless cellular base station is preferably connected to a public switched telephone network and is assigned a landline number. The cordless cellular base station acts as a conduit between the mobile station and the public switched telephone network. When the mobile station comes within range of a cordless cellular base station, it deregisters automatically from the cellular network and register with the cordless cellular base station. Once the mobile station is communicating with the cordless cellular base station, the cordless cellular base station communicates with the cellular network to instruct the cellular network to route all calls for mobile identification number to the cordless cellular base station's landline number. In addition, all calls placed on the mobile station are sent through the cordless cellular base station to the public switched telephone network. When the mobile station severs contact with the cordless cellular base station, the mobile station registers with the regional cellular base station of the regional cellular network.

US Patent:

20230052970, Feb 16, 2023

Filed:

Oct 3, 2022

Appl. No.:

17/937488

Inventors:

- Basel, CH
- Philadelphia PA, US
David Glass - Cambridge MA, US
Thomas Huber - Basel, CH
Julia Jascur - Basel, CH
Carl H. June - Merion Station PA, US
Jihyun Lee - Wynnewood PA, US
Joan Mannick - Cambridge MA, US
Michael C. Milone - Cherry Hill NJ, US
Leon Murphy - Cambridge MA, US
Avery D. Posey - Philadelphia PA, US
Huijuan Song - Shanghai, CN
Yongqiang Wang - Shanghai, CN
Lai Wei - Shanghai, CN
Qilong Wu - Brighton MA, US
Qiumei Yang - Shanghai, CN
Jiquan Zhang - Shanghai, CN

International Classification:

C07K 16/28
A61K 35/17
C07K 16/30
C07K 14/705
A61P 35/02
A61P 35/00
A61K 48/00
C07K 14/725
C12N 15/86

Abstract:

The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

US Patent:

20230026049, Jan 26, 2023

Filed:

Apr 28, 2022

Appl. No.:

17/661207

Inventors:

- Basel, CH
- Philadelphia PA, US
David Jonathan Glass - Cambridge MA, US
Brian Granda - Salisbury MA, US
John Hastewell - Cambridge MA, US
Andreas Loew - Boston MA, US
Joan Mannick - Cambridge MA, US
Michael C. Milone - Moorestown NJ, US
Leon Murphy - Cambridge MA, US
William Raj Sellers - Cambridge MA, US
Huijuan Song - Shanghai, CN
Brian Edward Vash - Cambridge MA, US
Jan Weiler - Cambridge MA, US
Qilong Wu - Shanghai, CN
Li Zhou - Cambridge MA, US

International Classification:

C07K 16/28
C07K 14/725
C07K 14/705
C07K 14/74
C12N 9/90
C12N 9/12
C07K 14/71
A61K 31/436
A61K 35/17

Abstract:

Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

US Patent:

20210309749, Oct 7, 2021

Filed:

Mar 16, 2021

Appl. No.:

17/203664

Inventors:

- Basel, CH
- Boston MA, US
David J. GLASS - Cambridge MA, US

International Classification:

C07K 16/28
A61P 9/04

Abstract:

The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.